KRROHealthcare · BiotechnologyThe 11 Wall Street analysts covering Korro Bio, Inc. hold a median 12-month price target of $22 — +64.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 24 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Korro Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (5): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KRRO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +64.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 19 May 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $15 |
| 19 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 May 2026 | Citigroup | Initiates | Buy | $21 |
| 18 May 2026 | Citigroup | Initiates | Buy | — |
| 13 Mar 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 13 Mar 2026 | Raymond James | Upgrade | Outperform | — |
| 19 Feb 2026 | Clear Street | Upgrade | Buy | — |
| 17 Feb 2026 | William Blair | Upgrade | Outperform | — |
| 29 Jan 2026 | Chardan Capital | Upgrade | Buy | — |
| 29 Jan 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 29 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 28 Jan 2026 | Cantor Fitzgerald | Upgrade | Overweight | — |
| 28 Jan 2026 | Oppenheimer | Upgrade | Outperform | — |
| 14 Nov 2025 | Jones Trading | Downgrade | Hold | — |
| 13 Nov 2025 | Cantor Fitzgerald | Downgrade | Neutral | — |
| 13 Nov 2025 | Chardan Capital | Downgrade | Neutral | — |
| 13 Nov 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 13 Nov 2025 | RBC Capital | Downgrade | Sector Perform | — |
| 13 Nov 2025 | William Blair | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRRO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 5% of US stocks
Cheaper than 49% of US stocks
Cheaper than 69% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 13% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Korro Bio, Inc. has a market value of $192.5M and an enterprise value of $119.6M.
Revenue in the twelve months to 30 June 2026: $2.4M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$106.6M, a −4477.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$68.3M.
Trailing P/E: −1.0×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Korro Bio, Inc. employs 57 people — $42K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Korro Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Korro Bio granted a non-statutory stock option to one newly hired employee, as disclosed under Nasdaq Listing Rule 5635(c)(4). The inducement grant was reported on August 14, 2026.
Why it matters — Investors tracking KRRO may note this as a routine compensation practice for new hires, though inducement grants can affect share dilution over time.
Zacks Investment Research upgraded Korro Bio, Inc. (KRRO) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The rating action may influence near-term stock movement.
Why it matters — A KRRO watcher would care because the upgrade signals improved confidence in the company's earnings outlook and could affect the stock's near-term performance.
Korro Bio reported its second quarter 2026 financial results and provided a corporate update. The company announced that its lead candidate KRRO-121 for hyperammonemia is on track for a first-in-human trial in the second half of 2026, received Orphan Drug Designation from the EMA for KRRO-121, nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency, and ended the quarter with $137.9 million in cash, with a runway into the second half of 2028.
Why it matters — KRRO watchers would care because the update confirms clinical program progress, a new regulatory milestone, a second development candidate, and a cash runway extending into 2028.
The 11 Wall Street analysts covering Korro Bio, Inc. have a median 12-month price target of $22, with estimates ranging from $10 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Korro Bio, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Korro Bio, Inc. 27 out of 100 across roughly 4,600 US stocks as at 24 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Aug 2026, Korro Bio, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +64.5% from the last close, and Ticker Nerd's factor model ranks Korro Bio, Inc. 27 out of 100 as at 24 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Korro Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $30 over the next 12 months.
Korro Bio Inc. is a biopharmaceutical company focused on developing genetic medicines based on RNA editing.
The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". Korro Bio granted a non-statutory stock option to one newly hired employee, as disclosed under Nasdaq Listing Rule 5635(c)(4). The inducement grant was reported on August 14, 2026.
Korro Bio Inc. is a biopharmaceutical company focused on developing genetic medicines based on RNA editing. The company uses its proprietary OPERA platform, short for oligonucleotide promoted editing of RNA, to create therapies that make precise changes at the RNA level rather than permanently altering DNA. Its current pipeline centers on treatments for rare and highly prevalent diseases, with lead programs targeting liver-directed and other genetically defined conditions such as hyperammonemia, alpha-1 antitrypsin deficiency, and additional disorders with high unmet medical need. Korro Bio Inc. develops its candidates through discovery, preclinical, and clinical-stage research, combining RNA biology, oligonucleotide chemistry, and disease-specific design to generate differentiated therapeutic options. The company is headquartered in Cambridge, Massachusetts, and its work positions it within the growing field of next-generation genetic medicine.
CEO Dr. Ram Aiyar MBA, Ph.D. · 57 employees · United States · https://www.korrobio.com